Skip to main content
Log in

Dose ranging for trials through biomarkers of drug effects

  • Published:
The journal of nutrition, health & aging


To test the hypothesis that excess amyloid deposition is an essential step in the pathophysiology of Alzheimer’s disease appropriate biomarkers are essential in selecting agents that modify amyloid formation or clearance. Cerebrospinal fluid concentrations of relevant analytes and PET measures of total brain load have been developed. These are directly applied to testing whether drugs reduce various soluble forms of amyloid as well as whether they enhance elimination of material deposited in brain parenchyma. The ideal profile of a drug that can fully test the amyloid hypothesis can be understood in terms of effects on currently available and future biomarkers. Dose selection for clinical trials should require a quantitative threshold effect on the most relevant biomarker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Miller, G. 2009. Neuroscience Methods, Alzheimer’s biomarker initiative hits its stride. Science 326: 386–389.

    Article  CAS  PubMed  Google Scholar 

  2. Siemers, E., Skinner, M., Dean, R.A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., and May, P.C. 2005. Safety, tolerability, and changes in amyloid ? concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126–132.

    Article  CAS  PubMed  Google Scholar 

  3. Rosen, L.B., Stone, J.A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al. 2006. O4-03-02: The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer’s and Dementia 2:S79–S79.

    Article  Google Scholar 

  4. Bateman, R.J., Siemers, E.R., Mawuenyega, K.G., Wen, G., Browning, K.R., Sigurdson, W.C., Yarasheski, K.E., Friedrich, S.W., Demattos, R.B., May, P.C., et al. 2009. A gamma-secretase inhibitor decreases amyloid-production in the central nervous system. Ann Neurol 66:48–54.

    Article  CAS  PubMed  Google Scholar 

  5. Yan, P., Bero, A.W., Cirrito, J.R., Xiao, Q., Hu, X., Want, Y., Gonzales, E., Holtzman, D.M., Lee, J-M. 2009. Characterizing the appearance and growth of amyloid plagues in APP/PS1 mice. J Neurosci 29: 10706–10714.

    Article  CAS  PubMed  Google Scholar 

  6. Bateman, R.J., Munsell, L.Y., Morris, J.C., Swarm, R., Yarasheski, K.E., and Holtzman, D.M. 2006. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856–861.

    Article  CAS  PubMed  Google Scholar 

  7. Bateman, R.J., Munsell, L.Y., Chen, X., Holtzman, D.M., and Yarasheski, K.E. 2007. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom 18:997–1006.

    Article  CAS  PubMed  Google Scholar 

  8. James, A.R., Nicoll, J.A.R., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P. N., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D. and Holmes, C. 2006. A species removal After A 42 immunization. J Neuropathol Exp Neurol 65: 1040–1048

    Article  Google Scholar 

  9. Siemers, ER, Friedrich, S., Dean RA, Sethuraman G, Demattos RB, Jennings D, Tamagnan G, Marek K, Seibyl J. 2008. Safety, tolerability and biomarker effects of an A monoclonal antibody administered to patients with Alzheimer’s disease. Alzheimer’s and Dementia: 4(Suppl 2):T774.

    Article  Google Scholar 

  10. Siemers, E.R., Demattos, R.B., Friedrich, S., Dean, R.A., Sethuraman, G., Margaret, R., Jennings, D., Tamagnan, G., Marek, K., Seibyl, J. and Paul, S.M. 2009. Use of a monoclonal anti-Aβ antibody with biochemical and imaging biomarkers to determine amyloid plaque load in patients with Alzheimer’s Disease (AD) and control subjects. American Academy of Neurology 2009 annual meeting, Seattle, WA; IN3-2.009.

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Potter, W.Z. Dose ranging for trials through biomarkers of drug effects. J Nutr Health Aging 14, 310–311 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: